Upregulated co-inhibitory molecules on peripheral lymphocytes included potentially druggable targets like LAG3, Tim3, or CTLA4, which are partially also highly expressed on residing lymphocytes in the TME of HL [45–47]. The gene discussed is CTLA4; the disease is Hodgkins lymphoma.